AYJ Stock Overview A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Valneva Historical stock prices Current Share Price €1.90 52 Week High €4.99 52 Week Low €1.74 Beta 1.05 1 Month Change 1.66% 3 Month Change -30.35% 1 Year Change -60.11% 3 Year Change -92.32% 5 Year Change -25.06% Change since IPO -83.15%
Recent News & Updates
Valneva SE Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® Dec 03 Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 Nov 13
Forecast to breakeven in 2024 Nov 13
Third quarter 2024 earnings released: €0.066 loss per share (vs €0.25 loss in 3Q 2023) Nov 09
New minor risk - Financial position Nov 08 Valneva SE to Report Nine Months, 2025 Results on Nov 13, 2025 See more updates
Valneva SE Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® Dec 03 Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 Nov 13
Forecast to breakeven in 2024 Nov 13
Third quarter 2024 earnings released: €0.066 loss per share (vs €0.25 loss in 3Q 2023) Nov 09
New minor risk - Financial position Nov 08 Valneva SE to Report Nine Months, 2025 Results on Nov 13, 2025
Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V Oct 17
New minor risk - Shareholder dilution Sep 17 Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate Sep 03
Second quarter 2024 earnings released: €0.19 loss per share (vs €0.12 loss in 2Q 2023) Aug 14
No longer forecast to breakeven Aug 14
Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq Jul 01
Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors Jun 27
First quarter 2024 earnings released: EPS: €0.42 (vs €0.13 loss in 1Q 2023) May 08
Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024 May 08
Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate Mar 27
Full year 2023 earnings released: €0.73 loss per share (vs €1.24 loss in FY 2022) Mar 24
New minor risk - Profitability Mar 22
Now 20% undervalued after recent price drop Mar 04
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ Mar 01
Forecast to breakeven in 2024 Feb 28
Valneva Se Announces Earnings Guidance for 2024 Feb 16
Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine Jan 11 Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024 Jan 10
Valneva SE Revises Earnings Guidance for the Full Year 2023 Dec 31
Valneva SE Revises Earnings Guidance for the Full Year 2023 Dec 30 Valneva SE to Report Q1, 2024 Results on May 07, 2024
No longer forecast to breakeven Dec 18
Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ® Dec 04
Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment Nov 29
Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment Nov 28
Valneva SE Announces Board Changes Nov 17
Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R) Nov 10
Third quarter 2023 earnings released: €0.25 loss per share (vs €0.68 profit in 3Q 2022) Nov 10
New minor risk - Share price stability Oct 25
Valneva Se Provides Revenue Guidance for the Year 2023 Sep 22
Second quarter 2023 earnings released: €0.12 loss per share (vs €1.34 loss in 2Q 2022) Sep 21
Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15 Sep 08
Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review Aug 30
Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553 Aug 29
New minor risk - Financial position Aug 22 Valneva SE announced a financing transaction Aug 18
Valneva Se Appoints Kathrin U Jansen to Supervisory Board Jun 22
Forecast breakeven date moved forward to 2023 Jun 17
Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet Jun 15 Valneva SE Provides Financial Guidance of 2023 May 06
First quarter 2023 earnings released: €0.13 loss per share (vs €0.24 loss in 1Q 2022) May 05
No longer forecast to breakeven Mar 24 Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate Feb 15 Valneva SE to Report First Half, 2023 Results on Aug 10, 2023
Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001 Jan 04
Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Candidate Dec 24 Valneva SE to Report Q1, 2023 Results on May 04, 2023
Investor sentiment improved over the past week Dec 06
Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate Dec 05 Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate Dec 02
ValnevaSE Appoints Dipal Patel as Chief Commercial Officer Nov 17
Valneva SE Reiterates Earnings Guidance for the Fiscal 2022 Nov 10 Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientific Conferences Oct 11
Valneva SE announced a financing transaction Oct 01
No longer forecast to breakeven Sep 15
Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001 Aug 30
Valneva SE Confirms World Health Organization Recommendations for its Inactivated COVID-19 Vaccine Aug 27
Valneva SE Initiates Rolling Submission of U.S. Food and Drug Administration Biologics License Application for Its Single Shot Chikungunya Vaccine Candidate Aug 19
Second quarter 2022 earnings released: €1.34 loss per share (vs €0.60 loss in 2Q 2021) Aug 14
Valneva SE Provides Revenue Guidance for the Fiscal Year 2022 Aug 11
Pfizer Inc. and Valneva SE Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15 Aug 09
Forecast breakeven date pushed back to 2024 Jul 27 Valneva Announces Initiation of the Phase 3 Study of Lyme Disease Vaccine Shareholder Returns AYJ DE Biotechs DE Market 7D -2.8% 1.1% -0.2% 1Y -60.1% -14.5% 7.0%
See full shareholder returns
Return vs Market: AYJ underperformed the German Market which returned 7% over the past year.
Price Volatility Is AYJ's price volatile compared to industry and market? AYJ volatility AYJ Average Weekly Movement 7.5% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: AYJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AYJ's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 1998 700 Thomas Lingelbach valneva.com
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Show more Valneva SE Fundamentals Summary How do Valneva's earnings and revenue compare to its market cap? AYJ fundamental statistics Market cap €322.47m Earnings (TTM ) -€7.42m Revenue (TTM ) €158.54m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AYJ income statement (TTM ) Revenue €158.54m Cost of Revenue €163.61m Gross Profit -€5.08m Other Expenses €2.34m Earnings -€7.42m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 20, 2025
Earnings per share (EPS) -0.046 Gross Margin -3.20% Net Profit Margin -4.68% Debt/Equity Ratio 79.4%
How did AYJ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 11:03 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Valneva SE is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Stéphan Dubosq Arkeon Finance Jean-Jacques Le Fur Bryan Garnier & Co Bruno Bulic Bryan Garnier & Co
Show 22 more analysts 
